SCHEMBL1708334

SCHEMBL1708334

Cc1ccc(C(=O)Cl)cc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.56
TSHR P16473 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
RAB9A P51151 2/20 0.51
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
MTOR P42345 6/20 0.46
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
DUSP3 P51452 1/20 0.41
PTPN5 P54829 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29477006 1.00 HPGD (0.56) HPGDTSHRSMN1; SMN2RAB9ANPC1
Dimethylamine SCHEMBL4264313 0.93 HPGD (0.50) HPGDTSHRSMN1; SMN2RAB9ANPC1
Diethylamine SCHEMBL4273667 0.87 HPGD (0.53) HPGDTSHRSMN1; SMN2RAB9ANPC1
SCHEMBL1707248 0.83 CHRNA1 (0.50) HPGDTSHRSMN1; SMN2RAB9ANPC1
SCHEMBL29935432 0.81 HPGD (0.58) HPGDTSHRSMN1; SMN2RAB9ANPC1
SCHEMBL407154 0.81 RAB9A (0.67) HPGDTSHRSMN1; SMN2RAB9ANPC1
SCHEMBL154862 0.81 HPGD (0.58) HPGDTSHRSMN1; SMN2RAB9ANPC1
SCHEMBL7683262 0.80 MAPT (0.40) HPGDTSHRSMN1; SMN2NPC1ALDH1A1
SCHEMBL30475402 0.80 SMN1; SMN2 (0.55) HPGDSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL40769 0.80 SMN1; SMN2 (0.55) HPGDSMN1; SMN2RAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692071-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS TOKUYAMA CORPORATION (JP) 2026-02-11 EP disclosed
US-12281060-B2 Remodilins for airway remodeling and organ fibrosis THE UNIVERSITY OF CHICAGO (US) 2025-04-22 US disclosed
US-20240415851-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2024-12-19 US disclosed
WO-2024202086-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS 株式会社トクヤマ 2024-10-03 WO disclosed
CN-118480001-A C-Kit (V559D)/PDGFR beta double-target allosteric inhibitor and preparation method, pharmaceutical composition and application thereof 贵州省天然产物研究中心 2024-08-13 CN disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20220194943-A1 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) 2022-06-23 US disclosed
US-20220177422-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS THE UNIVERSITY OF CHICAGO (US) 2022-06-09 US disclosed
WO-2022066917-A1 3-(6-AMINOPYRIDIN-3-YL)BENZAMIDE DERIVATIVES AS RIPK2 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-31 WO disclosed
US-20220040207-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2022-02-10 US disclosed
EP-1497271-A1 INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS Bayer Pharmaceuticals Corporation (US) 2005-01-19 EP disclosed
US-20040082625-A1 Calcium receptor modulating agents AMGEN INC. 2004-04-29 US disclosed
WO-2004011446-A1 INDANE, DIHYDROBENZOFURAN, AND TETRAHYDRONAPHTHALENE CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS BAYER PHARMACEUTICALS CORPORATION (US) 2004-02-05 WO disclosed
WO-2003099776-A1 CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES AMGEN INC. (US) 2003-12-04 WO disclosed
WO-2003089418-A1 INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS BAYER PHARMACEUTICALS CORPORATION (US) 2003-10-30 WO disclosed
EP-1201661-A1 HETEROAROMATIC RING COMPOUNDS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-02 EP disclosed
US-5237099-A Insecticidal substituted and unsubstituted benzoic acid 1-alkyl, 2-alkyl and 2-cycloalkylhydrazides AMERICAN CYANAMID COMPANY (US) 1993-08-17 US disclosed
EP-0228564-B1 NOVEL INSECTICIDAL DIACYLHYDRAZINE COMPOUNDS AMERICAN CYANAMID COMPANY (US) 1992-01-29 EP disclosed
US-4814349-A Insecticidal substituted and unsubstituted benzoic acid 1-alkyl, 2 alkyl and 2-cycloalkylhydrazides AMERICAN CYANAMID COMPANY (US) 1989-03-21 US disclosed
EP-0228564-A2 Novel insecticidal diacylhydrazine compounds AMERICAN CYANAMID COMPANY (US) 1987-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220040207-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA HIF1AN, RHOXF2, HIF1A HPGD 451/4885TSHR 3276/4885SMN1; SMN2 4731/4885
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC HPGD 2422/4885TSHR 4173/4885SMN1; SMN2 3760/4885
US-20040082625-A1 Calcium receptor modulating agents PTH1R, CASR, CALCR HPGD 1087/4885TSHR 32/4885SMN1; SMN2 4597/4885
US-20220177422-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS MYLK, MFAP1, FIBP HPGD 2289/4885TSHR 3401/4885SMN1; SMN2 4619/4885
US-20220194943-A1 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER EPHA1, EPHB2, EPHB1 HPGD 2748/4885TSHR 548/4885SMN1; SMN2 2715/4885
US-12281060-B2 Remodilins for airway remodeling and organ fibrosis MYLK, MFAP1, FIBP HPGD 2289/4885TSHR 3401/4885SMN1; SMN2 4619/4885
US-20240415851-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA HIF1AN, RHOXF2, HIF1A HPGD 451/4885TSHR 3276/4885SMN1; SMN2 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.